Max Hardy-Werbin

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Max Hardy-Werbin, Pedro Rocha, Oriol Arpí et al. · OncoImmunology · 2019 · 85 citations · Full text

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

David Casadevall, Sergi Clavé, Álvaro Taus et al. · Clinical Lung Cancer · 2017 · 84 citations

Cancer Immunosurveillance, Malignant Disease, Medicine +10

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma

Álvaro Taus, Laura Camacho, Pedro Rocha et al. · Clinical Lung Cancer · 2018 · 49 citations

Egfr Mutation Load, Oncology, Tumor Heterogeneity +11

CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC

Pedro Rocha, Max Hardy-Werbin, Dolores Naranjo et al. · Journal of Thoracic Oncology · 2018 · 35 citations

Inflammation, Cd103+cd8+ Lymphocytes Characterize, Allergy +9

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab

Max Hardy-Werbin, Oriol Arpí, Álvaro Taus et al. · OncoImmunology · 2017 · 33 citations · Full text

Immunology, Pathology, Metronomic Chemotherapy +18